# Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC

> **NCT07685197** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhou Chengzhi** · enrollment: 100 (estimated)

## Conditions studied

- NSCLC
- EGFR Activating Mutation
- EGFR-TKI-resistant Non-Small Cell Lung Cancer
- Trop2
- PET/CT Imaging

## Interventions

- **DIAGNOSTIC_TEST:** receive treatment with TROP2-targeted ADC and targeted molecular PET/CT imaging using ⁶⁸Ga-MY6349 injection

## Key facts

- **NCT ID:** NCT07685197
- **Lead sponsor:** Zhou Chengzhi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-07
- **Final completion:** 2028-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07685197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07685197, "Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07685197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*